Tissue Repair & Recovery
Peptide-based tissue repair is one of the most active research areas, with compounds targeting wound healing, tendon repair, muscle recovery, and post-surgical healing. Evidence ranges from Phase II human trials (TB-500, Thymosin Alpha-1) to promising animal models (BPC-157). No FDA-approved peptide exists specifically for tissue repair outside specific niche indications.
Relevant Peptides
Most studied; animal evidence strong. No human RCTs published.
Phase II human trials in wounds and cardiac. WADA-prohibited.
503A listed. Best clinical evidence for wound and skin repair.
Phase I/II for chronic wounds; antimicrobial + healing.
Phase II RCT for sarcoidosis neuropathy; tissue repair via IRR.
Anabolic; significant safety concerns.
Muscle-specific repair; animal data only.
The BPC-157 Paradox
BPC-157 has the most extensive animal evidence base of any research peptide — over 100 studies across multiple tissue types. Yet it has no completed human RCTs. This paradox (strong preclinical, absent clinical evidence) makes it simultaneously the most discussed and hardest to evaluate peptide in this category.
Regulatory Landscape for Tissue Repair
- GHK-Cu: Available through 503A compounding (topical); legitimate legal path
- BPC-157: Not on 503A list; not legally compoundable in US for human use
- TB-500: Not FDA approved; WADA prohibited
- LL-37: Research stage
What the Evidence Supports
The strongest clinical evidence for peptide-based tissue repair is in specific niches: wound healing (GHK-Cu, LL-37), cardiac repair (TB-500 Phase II), and neuropathic pain/repair (ARA-290). General “recovery peptide” marketing extrapolates beyond this evidence.
Stay current on peptide evidence
Weekly regulatory updates and study breakdowns. Free.